Eleventh Amendment to Services Agreement between Cara Therapeutics, Inc. and Bio Diligence Partners, Inc.

Contract Categories: Business Operations › Services Agreements
Summary

Cara Therapeutics, Inc. and Bio Diligence Partners, Inc. have agreed to extend their existing Services Agreement for one year, from July 1, 2016 to July 1, 2017. Under this amendment, Bio Diligence Partners will continue to receive annual compensation of $157,500, paid monthly, and reimbursement for 70% of the consultant's health insurance costs, paid quarterly. All other terms of the original agreement remain unchanged.

Read More Arrow
EX-10.1 2 d201221dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

 

June 30, 2016

Michael Lewis, Ph.D.

Bio Diligence Partners Inc.

This letter shall serve as an eleventh amendment to the Services Agreement dated July 2, 2004. It is hereby agreed to extend the Agreement from July 1, 2016 to July 1, 2017. Compensation described in Exhibit A of the Agreement, as previously amended, will continue at the rate of $157,500.00 per annum and paid on a monthly basis. The reimbursement for 70% of the health insurance cost for consultant shall continue, paid quarterly.

All other sections of the Agreement continue as written.

 

Cara Therapeutics, Inc.
By:  

/s/ Derek Chalmers

Name:   Derek Chalmers, Ph.D., D.Sc.
Title:   President & CEO
Bio Diligence Partners, Inc.
By:  

/s/ Michael Lewis

Name:   Michael Lewis, Ph.D.
Title:   President